ValiRx, a cancer therapeutics and diagnostics company, has successfully completed its first collaborative stage with Cancer Research Technology, undertaken through the company’s biopharmaceutical division ValiPharma. Trials completed under the collaborative agreement have shown positive in vivo results for ValiPharma’s therapeutic cancer compound, VAL 101.
According to ValiRx, data from the studies indicated tumor growth reduction was dose dependent with no unexpected side effects, indicating VAL 101 to be well tolerated within the effective dose range. The study also identified a potential suitable delivery system for the compound.
ValiRx has now obtained completed in vivo results from CRT and, based on these successful results, ValiRx will progress to late stage in vivo preclinical studies for VAL 101.
ValiRx’s therapeutic cancer compound VAL 101 is based on the company’s proprietary gene silencing technology, GeneICETM. Previous results have shown VAL 101’s efficacy in several cell-based cancer models, including prostate, ovarian and pancreatic cancers in vitro.
In vivo results to date have demonstrated and validated VAL 101’s efficiency as a novel cancer therapeutic in reducing pancreatic cancer tumour growth in an animal model after single administration, the company said.
Satu Vainikka, CEO of ValiRx, said: ValiRx is pleased to announce the continued development of our first GeneICETM cancer therapeutic, VAL 101. These in vivo results provide positive and evidentiary support for the use of our GeneICETM technology platform as a cancer therapeutic, proving our technology platform can be translated into real tumour growth inhibition. GeneICETM holds promise for application in a wide variety of disease areas.